Independent directory Public ClinicalTrials.gov records United States
Clear filters

These results were retrieved from the live ClinicalTrials.gov registry. Filters and sort order apply to this result list.

ClinicalTrials.gov public records Last synced Oct 18, 2026, 1:13 AM EDT

Data is sourced from official ClinicalTrials.gov public API records. Always review the official ClinicalTrials.gov record for the latest information.

Showing 97–120 of 742 matching trials from the live ClinicalTrials.gov search.
Completed Phase 4 Interventional Results available

Diphenhydramine for Acute Migraine

NCT01825941
Conditions
Migraine
Interventions
metoclopramide, diphenhydramine, placebo
Drug
Lead sponsor
Montefiore Medical Center
Other
Eligibility
21 Years to 64 Years
Enrollment
208 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2013 – 2014
U.S. locations
1
States / cities
The Bronx, New York
Conditions
Migraine
Interventions
Placebo ZNS, ZNS
Drug
Lead sponsor
Impax Laboratories, LLC
Industry
Eligibility
6 Years to 11 Years
Enrollment
374 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2017 – 2020
U.S. locations
47
States / cities
Phoenix, Arizona • Little Rock, Arkansas • Anaheim, California + 38 more
Completed Not applicable Interventional Results available

STOPAIN in the Treatment of a Single Migraine Attack

NCT01687101
Conditions
Migraine, Headache
Interventions
STOPAIN topical gel
Drug
Lead sponsor
Thomas Jefferson University
Other
Eligibility
18 Years to 65 Years
Enrollment
32 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2012 – 2013
U.S. locations
1
States / cities
Philadelphia, Pennsylvania
Conditions
Chronic Migraine Headache
Interventions
NEUROMARK System
Device
Lead sponsor
Neurent Medical
Industry
Eligibility
18 Years and older
Enrollment
24 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2024 – 2026
U.S. locations
7
States / cities
Birmingham, Alabama • Opelika, Alabama • Los Angeles, California + 4 more
Conditions
Migraine
Interventions
DFN-15 Dose A (treatment A), DFN-15 Dose B (treatment B), Placebo (treatment C)
Drug · Other
Lead sponsor
Dr. Reddy's Laboratories Limited
Industry
Eligibility
18 Years to 65 Years
Enrollment
63 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2015 – 2016
U.S. locations
6
States / cities
Long Beach, California • Santa Monica, California • Watertown, Massachusetts + 3 more
Conditions
Migraine Disorders
Interventions
Middle Meningeal Artery embolization
Device
Lead sponsor
Cerenovus, Part of DePuy Synthes Products, Inc.
Industry
Eligibility
18 Years to 65 Years
Enrollment
70 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2025 – 2029
U.S. locations
8
States / cities
Walnut Creek, California • Hartford, Connecticut • Buffalo, New York + 5 more
Conditions
Migraine
Interventions
Ketorolac, Placebo
Drug
Lead sponsor
Akron Children's Hospital
Other
Eligibility
8 Years to 18 Years
Healthy volunteers
Healthy volunteers not accepted
Timeline
Started 2012
U.S. locations
1
States / cities
Akron, Ohio
Conditions
Migraine Headache
Interventions
Aricept (donepezil hydrochloride)
Drug
Lead sponsor
Eisai Inc.
Industry
Eligibility
18 Years to 65 Years
Enrollment
89 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2003 – 2007
U.S. locations
4
States / cities
Chicago, Illinois • Springfield, Missouri • Mount Vernon, New York + 1 more
Conditions
Acute Migraine
Interventions
ZP-Zolmitriptan, Placebo
Drug
Lead sponsor
Zosano Pharma Corporation
Industry
Eligibility
18 Years to 65 Years
Enrollment
365 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2016 – 2017
U.S. locations
36
States / cities
Glendale, Arizona • Carlsbad, California • Huntington Beach, California + 32 more
Terminated Phase 4 Interventional Results available

Fremanezumab, Migraine and Sleep

NCT04693533
Conditions
Migraine Disorders, Sleep Disorder
Interventions
Fremanezumab Prefilled Syringe [Ajovy]
Drug
Lead sponsor
Beth Israel Deaconess Medical Center
Other
Eligibility
18 Years to 65 Years
Enrollment
22 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2021 – 2024
U.S. locations
1
States / cities
Boston, Massachusetts
Conditions
Migraine
Interventions
Galcanezumab, Erenumab
Drug
Lead sponsor
Eli Lilly and Company
Industry
Eligibility
18 Years to 55 Years
Enrollment
65 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2020 – 2021
U.S. locations
3
States / cities
Los Angeles, California • Newport Beach, California • Waterbury, Connecticut
Conditions
Migraine
Interventions
Magnesium, Placebo
Drug
Lead sponsor
Wake Forest University Health Sciences
Other
Eligibility
18 Years and older
Enrollment
100 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2025 – 2027
U.S. locations
1
States / cities
Oak Lawn, Illinois
Completed Phase 2 Interventional Accepts healthy volunteers Results available

Study to Determine Safety and Efficacy of B244 in Subjects With Episodic Migraine

NCT03488563
Conditions
Migraine
Interventions
B244, Vehicle
Biological
Lead sponsor
AOBiome LLC
Industry
Eligibility
18 Years to 65 Years
Enrollment
313 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2018 – 2019
U.S. locations
22
States / cities
Little Rock, Arkansas • Long Beach, California • Riverside, California + 19 more
Conditions
Migraine
Interventions
RELAXaHEAD Smartphone App Version 1, RELAXaHEAD Smartphone App Version 2
Behavioral
Lead sponsor
NYU Langone Health
Other
Eligibility
16 Years to 80 Years
Enrollment
450 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2023 – 2028
U.S. locations
1
States / cities
New York, New York
Conditions
Refractory Migraine
Interventions
Lidocaine hydrochloride, Methylprednisolone sodium succinate
Drug
Lead sponsor
The Cooper Health System
Other
Eligibility
18 Years and older
Enrollment
10 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2024 – 2025
U.S. locations
1
States / cities
Camden, New Jersey
Conditions
Migraine
Interventions
Rimegepant, Placebo
Drug
Lead sponsor
Pfizer
Industry
Eligibility
12 Years to 17 Years
Enrollment
200 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2024 – 2029
U.S. locations
27
States / cities
Phoenix, Arizona • Long Beach, California • Aurora, Colorado + 18 more
Conditions
Headache Disorders
Interventions
bion microstimulator
Device
Lead sponsor
Boston Scientific Corporation
Industry
Eligibility
18 Years and older
Enrollment
20 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2004 – 2007
U.S. locations
2
States / cities
Scottsdale, Arizona • Ann Arbor, Michigan
Conditions
Migraine
Interventions
Rimegepant, Various, No intervention
Drug · Other
Lead sponsor
Pfizer
Industry
Eligibility
16 Years to 49 Years · Female only
Enrollment
1 participant
Healthy volunteers
Healthy volunteers not accepted
Timeline
2021 – 2028
U.S. locations
1
States / cities
New York, New York
Conditions
Acute Migraine
Interventions
Nerivio
Device
Lead sponsor
Theranica
Industry
Eligibility
12 Years to 17 Years
Enrollment
60 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2019 – 2020
U.S. locations
12
States / cities
Aurora, Colorado • Hialeah, Florida • Miami, Florida + 8 more
Conditions
Migraine, Atrial Fibrillation
Interventions
Radiofrequency catheter ablation
Procedure
Lead sponsor
Texas Cardiac Arrhythmia Research Foundation
Other
Eligibility
18 Years to 75 Years
Enrollment
173 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2010 – 2014
U.S. locations
1
States / cities
Austin, Texas
Completed Not applicable Interventional Results available

The MOTS (Medication Overuse Treatment Strategy) Trial

NCT02764320
Conditions
Migraine
Interventions
Migraine Prophylactic Therapy Only, Discontinuation of Overused Medication
Other
Lead sponsor
Mayo Clinic
Other
Eligibility
21 Years and older
Enrollment
720 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2017 – 2021
U.S. locations
29
States / cities
Flagstaff, Arizona • Phoenix, Arizona • Scottsdale, Arizona + 21 more
Completed Phase 2 Interventional Results available

Assessment of LBR-101 In Chronic Migraine

NCT02021773
Conditions
Chronic Migraine
Interventions
LBR-101 High Dose, LBR-101 Low Dose, Placebo
Drug
Lead sponsor
Teva Branded Pharmaceutical Products R&D, Inc.
Industry
Eligibility
18 Years to 65 Years
Enrollment
264 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2014 – 2015
U.S. locations
57
States / cities
Gilbert, Arizona • Phoenix, Arizona • Scottsdale, Arizona + 51 more
Conditions
Irritable Bowel Syndrome (IBS), Functional Abdominal Pain, Fibromyalgia, Complex Regional Pain Syndrome (CRPS), Myofacial Pain, Chronic Daily Headaches, Migraine Headaches, Chronic Pain
Interventions
Mentorship
Behavioral
Lead sponsor
University of California, Los Angeles
Other
Eligibility
12 Years to 18 Years
Enrollment
27 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2009 – 2011
U.S. locations
1
States / cities
Los Angeles, California
Conditions
Migraine
Interventions
No intervention: We are testing for the presence of allodynia
Other
Lead sponsor
Thomas Jefferson University
Other
Eligibility
18 Years to 65 Years
Enrollment
28 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2006 – 2008
U.S. locations
1
States / cities
Philadelphia, Pennsylvania